Product Description: ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound[1]. ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease[2].
Applications: Neuroscience-Neurodegeneration
Formula: C8H18N2O4S
References: [1]John A. Hey, et al. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9): 849–861./[2]Hey JA, et al. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333.
CAS Number: 1034190-08-3
Molecular Weight: 238.30
Compound Purity: 98.83
Research Area: Neurological Disease
Solubility: H2O : 30 mg/mL (ultrasonic;warming;heat to 60°C)
Target: Amyloid-β
Deutsch
English
